Encompass Health

Encompass Health is a provider of healthcare services, providing both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. The company's inpatient rehabilitation hospitals provide specialized rehabilitative care across an array of diagnoses and deliver patient care services. The company's home health agencies provide home care services such as skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The company also provides hospice services such as pain control and symptom management, and emotional and spiritual support to terminally ill patients and their families.
  • TickerEHC
  • ISINUS29261A1007
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

With a more favourable environment, ENCOMPASS HEALTH improves to Slightly Positive

ENCOMPASS HEALTH (US), a company active in the Health Care Providers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 22, 2020, the closing price was USD 82.36 and its potential was estimated at USD 93.80.

Encompass Health Corp: 1 director sold

A director at Encompass Health Corp sold 6,650 shares at 75.220USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakout Brewing? With the 3200-3230 support level holding strong on the S&P 500, we remain constructive over the intermediate-term as outlined in our 11/3/20 Compass. Considering current market dynamics we see eventual decisive breakouts as the most likely outcome for the major averages, which justifies our positive outlook. At the same time, with the S&P 500, Russell 2000, and Nasdaq 100 climbing 7-12% in just over a week and all three testing logical resistance, we believe there is potential for some near-term backing-and-filling. Continue to buy dips. · Testing Resistance. Both t...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weigh...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: Many health care names are staging reversals and breaking above bullish bases, including IVC, CUTR, VREX, EHC, SEM, AMED, MD, HAE, RGEN, BIO, LCI, PBH, Semiconductor and semi-suppliers continue to be leadership (ex. ACLS, VECO, COHU, QRVO, SWKS, SYNA, CRUS, SMTC, QCOM) A number of auto component suppliers appear to be bottoming (ex. AXL, DAN, BWA)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Encompass Health Corp: 1 director sold

A director at Encompass Health Corp sold 6,650 shares at 75.220USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakout Brewing? With the 3200-3230 support level holding strong on the S&P 500, we remain constructive over the intermediate-term as outlined in our 11/3/20 Compass. Considering current market dynamics we see eventual decisive breakouts as the most likely outcome for the major averages, which justifies our positive outlook. At the same time, with the S&P 500, Russell 2000, and Nasdaq 100 climbing 7-12% in just over a week and all three testing logical resistance, we believe there is potential for some near-term backing-and-filling. Continue to buy dips. · Testing Resistance. Both t...

MarketLine Department

HCA Healthcare, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's HCA Healthcare, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by HCA Healthcare, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage...

With a more favourable environment, ENCOMPASS HEALTH improves to Slightly Positive

ENCOMPASS HEALTH (US), a company active in the Health Care Providers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 22, 2020, the closing price was USD 82.36 and its potential was estimated at USD 93.80.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch